Business Context and Reporting Period
Pulmatrix, Inc. filed a Form 8-K on April 1, 2019, reporting the entry into a binding term sheet with Cipla Technologies LLC. The agreement concerns the co-development and worldwide exclusive commercialization of Pulmazole (PUR1900), an inhaled formulation of itraconazole for treating allergic bronchopulmonary aspergillosis in asthma patients.
Key Financial Metrics and Transaction Terms
- Upfront Payment: Cipla will pay $22 million within 30 days of signing the definitive agreement.
- Intellectual Property: Pulmatrix will assign IP rights for Pulmazole to Cipla, with a license back for non-pulmonary applications. Cipla receives a perpetual, royalty-free license for Pulmatrix's iSPERSE technology.
- Development Funding: Pulmatrix must demonstrate $15 million in unencumbered cash prior to signing and dedicate $24 million to development within 30 days post-signing.
- Cost Sharing: After the initial $24 million is exhausted, development, regulatory, and commercialization costs will be split 50/50.
- Revenue Sharing: Parties will share equally in the total free cash flow from Pulmazole commercialization.
Material Changes and Conditions
The filing does not report changes to historical financial performance but outlines significant future obligations and asset transfers. A material condition precedent to the definitive agreement is Pulmatrix's ability to demonstrate at least $15 million of unencumbered cash. The filing also notes a 45-day exclusivity period during which Pulmatrix cannot solicit other offers for Pulmazole.
Outlook, Risks, and Contingencies
- Timeline: The definitive agreement is expected to be entered into during the second quarter of 2019, with Pulmatrix obligated to use commercially reasonable efforts to finalize it within 45 days of the term sheet.
- Right of First Offer/Refusal: Both parties have a right of first offer regarding Pulmazole assets. Cipla holds a right of first refusal for any future non-pulmonary indications or other inhaled anti-fungal products developed by Pulmatrix.
- Risk: The transaction is contingent on Pulmatrix meeting specific cash availability thresholds and successfully negotiating the definitive agreement.
Investor Verification Checklist
- Verify Pulmatrix's current unencumbered cash balance to confirm it meets the $15 million condition precedent.
- Confirm the execution of the definitive agreement within the expected Q2 2019 timeframe.
- Review the final definitive agreement for any deviations from the term sheet regarding cost-sharing caps or royalty structures.
- Assess the impact of the IP assignment on Pulmatrix's remaining asset portfolio and future licensing opportunities.